A new universal RP-HPLC column for peptide purification, and the use of novel flow-through media for the removal of acidic ion pairing agents and peptide free base formation are reported. The use of these two products, with SOPs, can substantially increase the throughput of peptide manufacture.
A new universal RP-HPLC column for peptide purification, and the use of novel flow-through media for the removal of acidic ion pairing agents and peptide free base formation are reported. The use of these two products, with SOPs, can substantially increase the throughput of peptide manufacture.
Getting a biotherapeutic synthetic peptide from the candidate identification stage through to production takes approximately 10 years. Initially small quantities, μg to g of many hundreds or thousands of peptides, 5 to 60 amino acids in length, are produced. To maximize throughput, standard methods of synthesis and purification are used. Reliable supplies of high quality synthesis supports, and reproducible, universally applicable columns for purification are needed to minimize failure at the synthesis stage, and eliminate method development at the purification step. A new universal purification column, VariTide RPC, and media, VariPure IPE (Ion Pair Extraction), for the removal of TFA or conversion of the peptide to the free base after purification, are tools for achieving this goal.
The VariTide RPC, 250 x 4.6 mm ID column, was used to chromatograph a mixture of peptides and small protein sequences, using 0.1% TFA in acetonitrile, and then to determine the optimum pH for purification by screening using: 0.1% TFA; 20 mM ammonium acetate, pH 5.5; 20 mM ammonium carbonate, pH 9.5; and 10 mM ammonium hydroxide, pH 10.4 with a linear gradient from 5 to 50% acetonitrile. To determine the capacity of the VariPure IPE media needed to remove TFA from the HPLC fractions, volumes of 0.1% TFA in 10–50% acetonitrile were passed though the media and the pH of the eluate measured. The media was considered to be fully exchanged, with the maximum amount of TFA removed, when the pH of the eluate was that of the 0.1% TFA solution.
To be universally applicable for the range of synthetic peptides, the pore size must be large enough to allow good mass transfer of the largest peptide but small enough to have good capacity. The separation of the peptide or protein mixture showed no band broadening compared to a 300Å size material, indicating good mass transfer over the required peptide size range. Figure 1 clearly shows the benefit of screening synthetic peptide resolution over a range of eluent pHs. An additional failure sequence from the solid phase synthesis is evident at high pH. From the screening runs, the optimum pH and gradient for the purification can be determined. The VariPure IPE media exchanges the TFA in the presence of the acetonitrile, with a minimum of 87% of theoretical capacity being used. When working at the recommended two-fold excess, 100 mg of the media exchanged 5 mL of 0.1% TFA solution–fraction from a preparative column.
Figure 1
A single column, VariTide RPC, can be used for synthetic peptide purification under acidic, neutral, and basic conditions. Peptides ranging in size from 5 to 60 amino acid residues are purified using one column, VariTide RPC, from μg to g scale. VariPure IPE media (100 mg) will free base 0.1 mmole of peptide and exchange 5 mL of 0.1% TFA solution.
Authors: Dr. Linda L. Lloyd, Dr. Paul A. Boguszewski
Company info
Polymer Laboratories, Varian, Inc.
Amherst Fields Research Park
160 Old Farm Road
Amherst, MA 01002
Tel: 413.253.9554
Fax: 413.253.2476
Email: PLinfo@polymerlabs.com
Website: www.polymerlabs.com
The Future of Cleanroom Construction: How Hybrid Solutions are Changing the Game
May 14th 2025Imagine a world where cleanroom facilities—essential for pharmaceutical manufacturing, biotechnology, and high-tech industries—are built with unparalleled speed, precision, and efficiency. That world is here, thanks to the hybrid construction approach. By blending traditional stick-built methods with modular and prefabricated solutions, companies are overcoming the limitations of conventional construction while ensuring compliance with stringent industry regulations. In this interview, we explore how hybrid cleanroom construction is transforming the industry, offering faster project timelines, improved quality control, and significant cost advantages. Join us as we delve into this game-changing approach with industry experts who are leading the charge in revolutionizing cleanroom infrastructure.
Mastering Antibody-Drug Conjugates
December 19th 2024In this episode, we explore BIOVECTRA’s capabilities in antibody-drug conjugate (ADC) manufacturing, from complex conjugation chemistry to synthesis of highly potent payloads. We’ll also showcase how BIOVECTRA’s extensive experience in complex chemistries and specialized small molecule manufacturing gives them a unique perspective, strengthening their approach to ADC production and ensuring clients receive custom solutions across all project stages.
Biophysical and Aggregate Characterization for the Development of Biologics
June 10th 2025This eBook explores how advanced particle analysis technologies are revolutionizing biologic drug development. It highlights the importance of accurately identifying and characterizing subvisible particles to ensure drug safety, stability, and regulatory compliance. Techniques like Backgrounded Membrane Imaging (BMI) and Fluorescence Membrane Microscopy (FMM) are often used for their capabilities in detecting protein aggregates and degraded excipients such as polysorbates. Case studies and experimental results demonstrate how these tools provide high-throughput, low-volume analysis that enhances decision-making in formulation screening and manufacturing.
Psilera, Hesperos Agree to Accelerate Organ-on-a-Chip Treatment for Frontotemporal Dementia
June 9th 2025The partnership leverages the Hesperos organ-on-a-chip platform in the preclinical development of Psilera’s lead compound targeting the progressive neurological disorder for which treatment options are few.